A Member of the Cancer Information Network
Cancer Information by State:
  arrow Patient Home   arrow Professional Home   arrow Newsletters   arrow Feedback Survey  
Main Menu
Quick Links
Information by Disease
Cancer News
Conference Coverage
Oncology Stocks
AZN$43.21-1.42 (-3.18%)
NVS$40.12-1.18 (-2.86%)
SNY$29.7-0.64 (-2.11%)
GSK$34.85-1.19 (-3.3%)
Lung Cancer Information Center
Folder Conference Coverage

 
People Current Topics
 
News Latest Lung Cancer News

Preoperative PET-CT Reduces Number of Thoracotomies but Does Not Improve Survival of Patients with NSCLC (7/2/2009)
Researchers from Denmark have reported that “The use of PET-CT for preoperative staging of NSCLC [non–small cell lung cancer] reduced both the total number of thoracotomies and the number of futile thoracotomies but did not affect overall mortality.” The details of this study appeared in the July 2, 2009 issue of the New England Journal of Medicine.

Lung Cancer Screening with Low-dose Computed Tomography Associated with High Rate of False Positives (6/12/2009)
Researchers from the National Institutes of Health have reported that individuals who undergo lung cancer screening with low-dose computed tomography (LDCT) are at a high risk for receiving false-positive results. The details of this study were presented at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida, on May 30.

Zactima™ Shows Promise Against Non–Small Cell Lung Cancer (6/8/2009)
Researchers affiliated with the ZODIAC international Phase III clinical trial have reported that the addition of Zactima™ (vandetanib) to Taxotere® (docetaxel) delayed time to progression among patients with previously treated, advanced non–small cell lung cancer (NSCLC). The details of this study were presented on May 30 at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida.

Combined Hormone Replacement Therapy Linked to Increased Death Rate from NSCLC (6/5/2009)
Researchers affiliated with the Women’s Health Initiative (WHI) have reported that menopausal women with non–small cell lung cancer (NSCLC) who receive combined hormone replacement therapy (HRT) with estrogen plus progestin are 61% more likely to die from the disease than their counterparts who received placebo. The details of this study were presented at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida on May 30.

Study Assesses Risk of Gastrointestinal Perforation in Patients Treated with Avastin® (6/1/2009)
Researchers from Stony Brook University Medical Center have reported that gastrointestinal perforation is a potentially serious side effect of Avastin® (bevacizumab). The details of this study appeared in the June, 2009 issue of Lancet Oncology.

More Lung Cancer News »

Lung Cancer Drug Pipeline

What's in the pipeline for Lung Cancer.
Newsletters

Register in our member center today to receive a monthly newsletter with clinical news, conference coverage, and current topic updates.
 
Information by Cancer Type

 Supportive Care Centers

 Physician Resources




© 1998-2007 CancerConsultants.com  All Rights Reserved.